How O’Day was paid
$28.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Daniel P. O’DayChairman and Chief Executive Officer | $1,795,192 | — | $15,238,402 | $4,500,060 | $4,848,120 | $2,055,424 | $28,437,198 |
| Andrew D. DickinsonChief Financial Officer | $1,116,654 | — | $4,321,741 | $1,299,976 | $1,956,266 | $70,979 | $8,765,616 |
| Johanna MercierChief Commercial and Corporate Affairs Officer | $1,182,269 | — | $4,564,517 | $1,299,976 | $2,150,901 | $102,980 | $9,300,643 |
| Dietmar Berger, M.D., Ph.D.Chief Medical Officer | $969,231 | $3,000,000 | $6,999,758 | $1,000,043 | $1,603,594 | $350,252 | $13,922,878 |
| Deborah H. TelmanFormer Executive Vice President, Corporate Affairs and General Counsel | $977,334 | — | $3,071,792 | $900,065 | — | $55,478 | $5,004,669 |
What changed and why
- $28.4MCEO total compensation increased to $28,437,198 in 2025 compared to $23,689,392 in 2024.
- $28.9BTotal product sales reached $28.9 billion, representing a 1% increase from 2024.
- $3MDr. Berger received a $3,000,000 sign-on bonus upon commencing employment as Chief Medical Officer in 2025.
- 37%Shareholders returned 37% in total shareholder return for the 2025 fiscal year.
- $20.8BGilead achieved record HIV product sales of $20.8 billion, driven by Biktarvy growth and the Yeztugo launch.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.